DESCOVY is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Remedyrepack Inc.. The primary component is Emtricitabine; Tenofovir Alafenamide Fumarate.
| Product ID | 70518-0230_8312635b-e182-4447-e053-2a91aa0a4b04 |
| NDC | 70518-0230 |
| Product Type | Human Prescription Drug |
| Proprietary Name | DESCOVY |
| Generic Name | Emtricitabine And Tenofovir Alafenamide Fumarate |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2019-02-16 |
| Marketing Category | NDA / NDA |
| Application Number | NDA208215 |
| Labeler Name | REMEDYREPACK INC. |
| Substance Name | EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE |
| Active Ingredient Strength | 200 mg/1; mg/1 |
| Pharm Classes | Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2017-02-16 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA208215 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2017-02-16 |
| Ingredient | Strength |
|---|---|
| EMTRICITABINE | 200 mg/1 |
| SPL SET ID: | eccee400-e198-4071-92a8-39c51948f699 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 61958-2002 | DESCOVY | emtricitabine and tenofovir alafenamide |
| 61958-2005 | DESCOVY | emtricitabine and tenofovir alafenamide |
| 70518-0230 | DESCOVY | emtricitabine and tenofovir alafenamide fumarate |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() DESCOVY 86170326 4876632 Live/Registered |
Gilead Sciences Ireland UC 2014-01-20 |